BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 22869151)

  • 21. The Role of Janus Kinase/STAT3 Pathway in Hematologic Malignancies With an Emphasis on Epigenetics.
    Zeinalzadeh E; Valerievich Yumashev A; Rahman HS; Marofi F; Shomali N; Kafil HS; Solali S; Sajjadi-Dokht M; Vakili-Samiani S; Jarahian M; Hagh MF
    Front Genet; 2021; 12():703883. PubMed ID: 34992627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia.
    Degryse S; Cools J
    J Hematol Oncol; 2015 Jul; 8():91. PubMed ID: 26208852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytokine Signaling in Tumor Progression.
    Lee M; Rhee I
    Immune Netw; 2017 Aug; 17(4):214-227. PubMed ID: 28860951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma.
    Ou A; Ott M; Fang D; Heimberger AB
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33498872
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Downes CE; McClure BJ; McDougal DP; Heatley SL; Bruning JB; Thomas D; Yeung DT; White DL
    Front Cell Dev Biol; 2022; 10():942053. PubMed ID: 35903543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia.
    Downes CEJ; McClure BJ; Bruning JB; Page E; Breen J; Rehn J; Yeung DT; White DL
    NPJ Precis Oncol; 2021 Aug; 5(1):75. PubMed ID: 34376782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KLC1-ROS1 Fusion Exerts Oncogenic Properties of Glioma Cells via Specific Activation of JAK-STAT Pathway.
    Fujii T; Nakano Y; Hagita D; Onishi N; Endo A; Nakagawa M; Yoshiura T; Otsuka Y; Takeuchi S; Suzuki M; Shimizu Y; Toyooka T; Matsushita Y; Hibiya Y; Tomura S; Kondo A; Wada K; Ichimura K; Tomiyama A
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting gene level sensitivity to JAK-STAT signaling perturbation using a mechanistic-to-machine learning framework.
    Cheemalavagu N; Shoger KE; Cao YM; Michalides BA; Botta SA; Faeder JR; Gottschalk RA
    bioRxiv; 2023 May; ():. PubMed ID: 37292918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fine-Tuning Cytokine Signals.
    Lin JX; Leonard WJ
    Annu Rev Immunol; 2019 Apr; 37():295-324. PubMed ID: 30649989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK Kinases in Health and Disease: An Update.
    Laurence A; Pesu M; Silvennoinen O; O'Shea J
    Open Rheumatol J; 2012; 6():232-44. PubMed ID: 23028408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unraveling the Immunogenetics of STAT Proteins: Clinical Perspectives on Gain-of-Function and Loss-of-Function Variants.
    Meesilpavikkai K; Hirankarn N; Dalm VASH; Hagen PMV; Dik WA; IJspeert H
    Asian Pac J Allergy Immunol; 2024 Jun; 42(2):105-122. PubMed ID: 38710647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring the molecular mechanisms between lymphoma and myelofibrosis.
    Wang JN; Li Y
    Am J Transl Res; 2024; 16(3):730-737. PubMed ID: 38586105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
    Quintás-Cardama A; Verstovsek S
    Clin Cancer Res; 2013 Apr; 19(8):1933-40. PubMed ID: 23406773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.
    Springuel L; Renauld JC; Knoops L
    Haematologica; 2015 Oct; 100(10):1240-53. PubMed ID: 26432382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.
    Waldmann TA
    Mol Cell Endocrinol; 2017 Aug; 451():66-70. PubMed ID: 28214593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.
    Derenzini E; Younes A
    Expert Opin Investig Drugs; 2013 Jun; 22(6):775-85. PubMed ID: 23442043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of Jak/STAT signaling in immunity and disease.
    Villarino AV; Kanno Y; Ferdinand JR; O'Shea JJ
    J Immunol; 2015 Jan; 194(1):21-7. PubMed ID: 25527793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours.
    Thomas SJ; Snowden JA; Zeidler MP; Danson SJ
    Br J Cancer; 2015 Jul; 113(3):365-71. PubMed ID: 26151455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective.
    Staerk J; Constantinescu SN
    JAKSTAT; 2012 Jul; 1(3):184-90. PubMed ID: 24058768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK-STAT signaling in cancer: From cytokines to non-coding genome.
    Pencik J; Pham HT; Schmoellerl J; Javaheri T; Schlederer M; Culig Z; Merkel O; Moriggl R; Grebien F; Kenner L
    Cytokine; 2016 Nov; 87():26-36. PubMed ID: 27349799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.